Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation

被引：581

作者：

Kotton, Camille N. ^{[1
]}

Kumar, Deepali ^{[2
]}

Caliendo, Angela M. ^{[3
]}

Asberg, Anders ^{[4
]}

Chou, Sunwen ^{[5
]}

Danziger-Isakov, Lara ^{[6
]}

Humar, Atul ^{[7
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA

[2] Univ Alberta, Edmonton, AB, Canada

[3] Brown Univ, Alpert Med Sch Brown, Providence, RI 02912 USA

[4] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway

[5] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA

[7] Univ Alberta, Dept Med, Alberta Transplant Inst, Edmonton, AB, Canada

来源：

TRANSPLANTATION | 2013年 / 96卷 / 04期

关键词：

Cytomegalovirus; CMV; Ganciclovir; Prevention; Prophylaxis; Resistance; Treatment; Valganciclovir; T-CELL RESPONSES; DRUG-RESISTANT CYTOMEGALOVIRUS; EPSTEIN-BARR-VIRUS; EXTENDED VALGANCICLOVIR PROPHYLAXIS; BRONCHIOLITIS OBLITERANS SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; HEPATIC-ARTERY THROMBOSIS; MANNOSE-BINDING LECTIN; VS. ORAL GANCICLOVIR; LONG-TERM RECIPIENT;

D O I：

10.1097/TP.0b013e31829df29d

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ transplantation, resulting in significant morbidity, graft loss, and adverse outcomes. Management of CMV varies considerably among transplant centers but has been become more standardized by publication of consensus guidelines by the Infectious Diseases Section of The Transplantation Society. An international panel of experts was reconvened in October 2012 to revise and expand evidence and expert opinion-based consensus guidelines on CMV management, including diagnostics, immunology, prevention, treatment, drug resistance, and pediatric issues. The following report summarizes the recommendations.

引用

页码：333 / 360

页数：28

共 272 条

[1] Human Cytomegalovirus-Specific T-Cell Immune Reconstitution in Preemptively Treated Heart Transplant Recipients Identifies Subjects at Critical Risk for Infection [J].

Abate, Davide ;

Fiscon, Marta ;

Saldan, Alda ;

Cofano, Simona ;

Mengoli, Carlo ;

Sgarabotto, Dino ;

d'Agostino, Chiara ;

Barzon, Luisa ;

Cusinato, Riccardo ;

Toscano, Giuseppe ;

Feltrin, Giuseppe ;

Gambino, Antonio ;

Gerosa, Gino ;

Palu, Giorgio .

JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (06) :1974-1980

[2] Evaluation of Cytomegalovirus (CMV)-Specific T Cell Immune Reconstitution Revealed That Baseline Antiviral Immunity, Prophylaxis, or Preemptive Therapy but not Antithymocyte Globulin Treatment Contribute to CMV-Specific T Cell Reconstitution in Kidney Transplant Recipients [J].

Abate, Davide ;

Saldan, Alda ;

Fiscon, Marta ;

Cofano, Simona ;

Paciolla, Adriana ;

Furian, Lucrezia ;

Ekser, Burcin ;

Biasolo, Maria Angela ;

Cusinato, Riccardo ;

Mengoli, Carlo ;

Bonfante, Luciana ;

Rossi, Barbara ;

Rigotti, Paolo ;

Sgarabotto, Dino ;

Barzon, Luisa ;

Palu, Giorgio .

JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (04) :585-594

[3] Cytomegalovirus DNA stability in EDTA anti-coagulated whole blood and plasma samples [J].

Abdul-Ali, Deborah ;

Kraft, Colleen S. ;

Ingersoll, Jessica ;

Frempong, Mona ;

Caliendo, Angela M. .

JOURNAL OF CLINICAL VIROLOGY, 2011, 52 (03) :222-224

[4]

[Anonymous], GRADE STRENGTH REC Q

[5]

[Anonymous], PHYS DESK REFERENCE

[6] Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation [J].

Arthurs, Supha K. ;

Eid, Albert J. ;

Pedersen, Rachel A. ;

Kremers, Walter K. ;

Cosio, Fernando G. ;

Patel, Robin ;

Razonable, Raymund R. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (06) :840-846

[7] Delayed-onset primary cytomegalovirus disease after liver transplantation [J].

Arthurs, Supha K. ;

Eid, Albert J. ;

Pedersen, Rachel A. ;

Dierichising, Ross A. ;

Kremers, Walter K. ;

Patel, Robin ;

Razonable, Raymund R. .

LIVER TRANSPLANTATION, 2007, 13 (12) :1703-1709

[8] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].

Asberg, A. ;

Humar, A. ;

Rollag, H. ;

Jardine, A. G. ;

Mouas, H. ;

Pescovitz, M. D. ;

Sgarabotto, D. ;

Tuncer, M. ;

Noronha, I. L. ;

Hartmann, A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113

[9] Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients [J].

Asberg, A. ;

Jardine, A. G. ;

Bignamini, A. A. ;

Rollag, H. ;

Pescovitz, M. D. ;

Gahlemann, C. C. ;

Humar, A. ;

Hartmann, A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (08) :1881-1888

[10] Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients [J].

Asberg, A. ;

Humar, A. ;

Jardine, A. G. ;

Rollag, H. ;

Pescovitz, M. D. ;

Mouas, H. ;

Bignamini, A. ;

Toez, H. ;

Dittmer, I. ;

Montejo, M. ;

Hartmann, A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1205-1213

← 1 2 3 4 5 6 7 8 9 10 →